The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin’s patents would be invalidated; (ii) the Company’s litigation was preventing it from effectuating a successful takeover; (iii) Defendants were downplaying the true threat the ongoing Abbreviated New Drug Applications ("ANDA") litigation posed to the Company’s business and future prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.